Publications

1. Academic-Community partnership outreach program to improve accrual of underrepresented minority women to breast cancer clinical trials in Southern California. Yuan Y., Uppala P., S. Lum et al. Journal of American Board of family Medicine (Submitted Feb 2015)
2. Chen C.H., Cheng  C.T., Yuan Y., Ann D. et al, Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment. Oncotarget (Submitted December, 2014)
3. Mortimer J., Jung J., Yuan Y., Dadwal S. et al. Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. Breast Cancer Res Treat, 2014; 148 (3):563-570.
4. Molecular Biology of Breast Cancer (Book Chapter) J. Kurreck and CA Stein, Molecular Medicine, Wiley, 2015. 
5. Khan S., Bennit H.F., Turay D., Perez M., Mirshahidi S., Yuan Y., Wall N.R. Early diagnostic value of Survivin and its alternative splice variants in breast cancer.  BMC Cancer.2014, 14:176 
6. Yuan Y., Yu M Liao; Chung T Hsueh; Hamid R Mirshahidi. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. Journal of Hematology & Oncology, 2011 Apr 20; 4:16
7. Yuan Y., Cohen D., Love E, Yaw M, Levinson B, Nicol SJ, Hochster HS. et al. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors. Cancer Chemotherapy Pharmacol  2011 Aug;68(2):371-8
8. Yuan Y., Wieczorek R., Green L.D., Cook P., Ballard H., Araten D.J. et al. Multiple Myleoma Involving Skin and Pulmonary Parenchyma after Autologous Stem Cell Transplantation. Journal of Hematology & Oncology 2009 Nov 13;2:48
9. Yuan Y., Orlow S.J., Curtin J., Downey A., Muggia F. Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo. E cancer medical science .2008;2:111
10. Petrovan R.J., Yuan Y., Curtiss L.K. Expression of the Lystbeige mutation is atheroprotective in chow-fed apolipoprotein E-deficient mice. J Lipid Res. 2008 Feb;49(2):429-37
11. Zhu Y., Liao HL., Xie X., Yuan Y., Shemerman MB et al, Oxidized LDL downregulates APT-binding cassette transporter-1 in human vascular endothelial cells via inhibiting liver X receptor (LXR). Cardiovasc Res.  2005 Dec1;68 (3):425-32
12. Zhu Y., Liao HL., Niu XL, Yuan Y, Stemerman MB et al, Low density lipoprotein induces eNOS translocation to membrane caveolae: the role of RhoA activation and stress fiber formation. Biochim Biophys Acta.2003  Dec 30;1635(2-3):117-26
13. Yuan Y., Verna L.K., Stemerman M.B., et al., Cholesterol enrichment upregulates intercellular adhesion molecule-1 in human vascular endothelial cells. Biochimica Biophysica Acta  2001 Dec 30; 1534(2-3): 139-48
14. Y.Zhu, Liao H.L., Wang N., Y.Yuan, Stemerman M.B., et al., Lipoprotein promotes caveolin-1 and ras translocation to caveolae: role of cholesterol in endothelial signaling, Arterioscler. Thromb. Vasc. Biol., 2000,( 20): 2465-247
15. Yuan Y., Zhou C.N. Photodynamic therapy induced cell apoptosis (appraisal in Chinese) Chinese Journal of Laser Medicine. 1996, Vol. 5(2): 111-115

Meeting Presentations:

1. Yuan Y., Voral N., Hurria A., et.al. Association of baseline pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with relative dose intensity (RDI) in women with breast cancer (BC) undergoing (neo) adjuvant chemotherapy (chemo). (2015 Annual ASCO Meeting, submitted # 148934)
2. Mortimer JE, Jung J., Yuan Y., Kruper L.et al. Skin, Nail, and Staphylococcal infections associated with the addition of pertuzumab to trastuzumab-based chemotherapy. (2015 Annual ASCO Meeting, submitted # 150188)
3. Chen C.H., Cheng C.T., Yuan Y., Wu R., Ann D. et al, MARCKS phosphorylation is associated with breast cancer malignancy and paclitaxel unresponsiveness. (2015 Annual ASCO Meeting, submitted )
4. Yuan Y., Arti Hurria et al. Association of baseline pro-inflammatory (IL-6, CRP) and coagulation (D-dimer) markers with baseline functional status in women with breast cancer (BC) undergoing chemotherapy. 2014 SABCS
5. Mortimer JE, Yuan Y, Stewart D, Chung S, Kruper L, Wong LC, Mendelsohn M, Behrendt C, Dadwal S, Tegtmeier B. Skin infections associated with the addition of pertuzumab to trastuzumab-containing chemotherapy. 2014 SABCS
6. Yuan Y., Uppala P. et al. Accrual of under-represented minority women to breast cancer clinical trials in Inland Empire, California. 2012 ASCO Breast Cancer Symposium. Sept. 2012 Poster discussion session B (abstr 64).
7. Yuan Y., Uppla P. et al. Accrual of underrepresented minority women to breast cancer clinical trials in the inland empire California. J Clin Oncol  2011, 29: 2011 (suppl; abstr 9058)
8. Yuan Yuan., Siu-Fun Wong., Nathan Wall et al. Surviving and its splicing variants in breast cancer patients. South Western Oncology Group (SWOG) Semi-Annual Meeting. Breast Committee presentation. April, 2011
9. Yuan Y., Ma H., Cohen D., Hochster H.S. et al. Activity and tolerance of biweekly CapeOx-Cetuximab in 1st line therapy of metastatic colorectal cancer (mCRC): relation to K-ras mutation status. J Clin Oncol  27, 2009 (suppl; abstr e15018)
10. Yuan Y., Ma H., Cohen D., Hochster H.S. et al. Activity and tolerance of biweeklyCapeOx-Cetuximab in first-line therapy of metastatic colorectal cancer (mCRC) and K-ras influences. 2009 ASCO GI symposium. (abstr 341)
11. Cohen D., Ma H., Yuan Y., Hochman T., Hochster H.S. Biweekly cetuximab (C), oxaliplatin (Ox), and capecitabine (Cape) in first line therapy of metastatic colorectal cancer (mCRC): Preliminary results on toxicity and K-ras status. J Clin Oncol 26: 2008 (May 20 suppl; abstr 15060)
12. Yuan Y., Omene C., Green D., Araten D., Ballard H. A Relapsed Multiple Myeloma with Multiple Soft Tissue Plasmacytoma of the Extremities and Diffuse Pulmonary Parenchymal Involvement. Annual Research Conference of Department of Medicine, New York University Medical Center, 2008
13. Petrovan R.J., Yuan Y., Curtiss L.K. Atherosclerosis in Apolipoprotein E-Deficient Mice with the Lystbeige Mutation. Annual Research Conference of Department of Medicine, New York University Medical Center, 2004
14. Yuan Y., Wang, N., Zhu, Y., Liao, HL., Stemerman,  M.B. and Verna, L.K. Cholesterol-induced cell signaling in the endothelium. International Society of Thrombosis and Homeostasi , Paris, France. July 8, 2001
15. Yuan Y., Stemerman M.B., et al. Cholesterol causes human umbilical vein endothelial cell activation. The FASEB Journal Vol. 14(4): A414, 2000

Clinical Trials as Principle Investigator:

1. COH IRB-13435: A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease.
2. COH IRB-14036: Phase I/IB Trial of Eribulin and Everolimus in Patients with Triple Negative Metastatic Breast Cancer
3. Cooperative Group Trials as Institutional PI from previous Institution (Loma Linda University)
4. NSABP FB-7: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide and Postoperative Trastuzumab in Women with Locally Advanced HER2-positive Breast Cancer.
5. SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.
6. NSABP B-40: Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery.
7. NSABP B-43:Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy.
8. CALGB 40502: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer.
9. SWOG S-0500: A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment.
10. SWOG S-0800: A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel(Nab-Paclitaxel ) with or without Bevacizumab, either proceed by or followed by Q2 week Doxorubicin and cyclophosphamide plus Pegfilgrastim as Neoadjvuant Therapy for inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer.